Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation

2023386 citationsJournal Articlegreen Open Access

Authors

Jeff S. Healey · Montreal Heart Institute

Renato D. Lópes · Duke University

Christopher B. Granger · Duke University

Marco Alings · Montreal Heart Institute

Léna Rivard · Montreal Heart Institute

William F. McIntyre · Montreal Heart Institute

Dan Atar ·

Abstract

Among patients with subclinical atrial fibrillation, apixaban resulted in a lower risk of stroke or systemic embolism than aspirin but a higher risk of major bleeding. (Funded by the Canadian Institutes of Health Research and others; ARTESIA ClinicalTrials.gov number, NCT01938248.).

Topics & Keywords

Atrial Fibrillation Management and Outcomes Cardiac Arrhythmias and Treatments Cardiac electrophysiology and arrhythmias

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 390, Issue 2, pp. 107-117

DOI: 10.1056/nejmoa2310234

Field-Weighted Citation Impact: 84.01